Quick Answer
ABVC BIOPHARMA, INC. reported Gross Profit of $508.8 thousand for the year ending 2024.
- ABVC BIOPHARMA, INC. showed an increase of +440.1% in Gross Profit from 2023 to 2024.
- This data is from ABVC BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2014 to 2024 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2015: $0.00 | Q1 2016: -$32.00 | Q4 2016: $70.0 thousand | Q2 2017: $90.0 thousand | Q2 2018: $910.00 | Q3 2018: $210.00 | Q1 2019: $210.7 thousand | Q2 2019: $178.4 thousand | Q3 2019: $194.9 thousand | Q1 2020: $74.8 thousand | Q2 2020: $222.3 thousand | Q3 2020: $106.9 thousand | Q1 2021: $261.9 thousand | Q2 2021: $30.8 thousand | Q3 2021: $98.6 thousand | Q1 2022: $23.8 thousand | Q2 2022: $304.5 thousand | Q3 2022: $31.5 thousand | Q1 2023: $68.0 thousand | Q2 2023: -$66.9 thousand | Q3 2023: -$13.7 thousand | Q1 2024: $928.00 | Q2 2024: $117.0 thousand | Q3 2024: $389.0 thousand | Q3 2025: $796.0 thousand.
- Historical annual values: Fiscal year 2024: $508.8 thousand | Fiscal year 2023: -$149.6 thousand | Fiscal year 2022: $683.4 thousand | Fiscal year 2021: $350.7 thousand | Fiscal year 2020: $464.3 thousand | Fiscal year 2019: $681.6 thousand | Fiscal year 2018: -$178.3 thousand | Fiscal year 2016: -$32.00 | Fiscal year 2015: $2.8 thousand | Fiscal year 2014: $0.00 | Fiscal year 2014: $0.00.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: